Système complémentaire

<p>C3a Receptor Agonist activates C3aRs, inhibits neutrophil mobilization in ischemia, and promotes neural progenitor differentiation.</p>

NDT 9513727 is a potent, selective and competitive C5aR1 inverse agonist for the study of inflammatory and immune disorders.

Complement C5-IN-1 is a small-molecule inhibitor of complement component 5 protein (C5).

EG00229 blocks VEGF-A/NRP1 binding, IC50 of 3 μM; doesn't affect VEGFR-1/2. It's an NRP1 antagonist.

EG01377 is a NRP1 antagonist with antiangiogenic, antimigratory, and antitumor activity, Kd 1.32 μM, IC50s 609 nM for NRP1-a1/b1, inactive on NRP2.

Factor B-IN-2 is a potent inhibitor (IC50: 1.5 μM) of complement factor B. Factor B-IN-2 can be used to study inflammatory and immune-related diseases.

Factor D inhibitor 6 is a potent, highly selective, and orally active compound that specifically inhibits the activity of factor D (FD) with an IC50 of 30 nM and a Kd of 6 nM. It does not exhibit inhibitory effects against factor B, classical and lectin complement-pathway activation, or a broad array of receptors, ion channels, kinases, and proteases.

C5aR-IN-1, a potent C5aR inhibitor, may aid in researching autoimmune and inflammatory diseases.

W-54011: potent non-peptide C5a receptor blocker; binds 125I-C5a (Ki=2.2nM); stops Ca2+ movement, chemotaxis, ROS in neutrophils (IC50=1.6-3.1nM).

Iptacopan (LNP023) is an inhibitor with high affinity to factor B, with a KD value of 7.9 nM and an IC50 value of 10 nM. Cost-effective and quality-assured.

<p>Pelecopan (BCX9930), an oral complement factor D inhibitor, prevents hemolysis in PNH (IC50=14.3 nM).</p>

Factor B-IN-4 is a potent inhibitor (IC50: 1 μM) of complement factor B. Factor B-IN-4 can be used to study inflammatory and immune-related diseases.

Factor B-IN-3 is a potent inhibitor of complement factor B. Factor B-IN-3 can be used to study inflammatory and immune-related diseases.

Refinicopan is a complement factor D inhibitor with an IC50 of 10 nM, demonstrating an inhibition activity on rabbit erythrocyte hemolysis with an IC50 of 41 nM. It possesses excellent pharmacokinetic and pharmacodynamic properties.

C5aR-IN-3, a potent C5aR inhibitor, may treat autoimmune and inflammatory diseases.

4-Octylphenol is an endocrine disruptor with gender-specific effects on male germ cells, significantly reducing the mitotic index and the number of spermatogonia. It also causes inflammatory damage in the gills of carp by activating the complement system through the C3a/C3a receptor (C3a/C3aR) axis and C5a/C5a receptor 1 (C5a/C5aR1) axis. Furthermore, 4-Octylphenol induces immune suppression by disrupting the balance between helper T (Th) cells 1/Th2 and regulatory T (Treg)/Th17 cells, and triggers inflammatory damage through the Toll-like receptor 7 (Toll-like Receptor (TLR))/inhibitor κBα/nuclear factor κB (TLR7/IκBα/NF-κB) pathway.

(Rel)-Factor B-IN-5 is a complement factor B inhibitor that can be used to study diseases associated with activation of the alternative complement pathway.

<p>TLQP-21 TFA （TLQP-21 Trifluoroacetate） 是一种 VGF 衍生肽，可通过结合后折叠机制激活C3aR1 受体。</p>

<p>TLQP-21 TFA is a VGF-derived peptide, C3aR1 agonist (mouse EC50: 10.3μM; human EC50: 68.8μM), that raises intracellular Ca2+ for nociception research.</p>